NCT02083692 is a EARLY_PHASE1 clinical trial of Metformin in Head and Neck Squamous Cell Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

What drugs are being tested in NCT02083692?

Interventions in NCT02083692: Metformin.

What condition does NCT02083692 study?

NCT02083692 studies Head and Neck Squamous Cell Cancer.

Is NCT02083692 still recruiting?

NCT02083692 is currently completed. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT02083692

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling

Completed EARLY_PHASE1 Last updated 15 May 2025

What this trial tests

EARLY_PHASE1 trial testing Metformin in Head and Neck Squamous Cell Cancer in 50 participants. Completed in 6 April 2017.

Timeline

5 September 2013

Primary endpoint
9 May 2016

6 April 2017

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	50
Start date	5 September 2013
Primary completion	9 May 2016
Estimated completion	6 April 2017
Sites	1 location across United States

Drugs / interventions tested

Metformin (metformin) — full drug profile →

Conditions studied

Head and Neck Squamous Cell Cancer — all drugs for Head and Neck Squamous Cell Cancer →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Who can join

Adults 18 to 80, any sex, with Head and Neck Squamous Cell Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the effect of metformin in tumor metabolism in patients with head and neck cancer by evaluating metformin's ability to decrease TOMM20 expression in squamous carcinoma cells and decrease MCT4 expression in fibroblasts.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Metabolism, metabolites, and macrophages in cancer.
Li M, Yang Y, Xiong L, Jiang P, et al · · 2023 · cited 305× · PMID 37491279 · DOI 10.1186/s13045-023-01478-6
Repurposing metformin for cancer treatment: current clinical studies.
Chae YK, Arya A, Malecek MK, Shin DS, et al · · 2016 · cited 233× · PMID 27004404 · DOI 10.18632/oncotarget.8194
Repurposing metformin for the prevention of cancer and cancer recurrence.
Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. · · 2017 · cited 224× · PMID 28776080 · DOI 10.1007/s00125-017-4372-6
Targeting hypoxic response for cancer therapy.
Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, et al · · 2016 · cited 73× · PMID 26859576 · DOI 10.18632/oncotarget.7229
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Cai Y, Dodhia S, Su GH. · · 2017 · cited 67× · PMID 28108737 · DOI 10.18632/oncotarget.14729
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M, Yaniv B, Palackdharry S, Lehn MA, et al · · 2022 · cited 61× · PMID 36328378 · DOI 10.1136/jitc-2022-005632
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.
Curry J, Johnson J, Tassone P, Vidal MD, et al · · 2017 · cited 55× · PMID 28185288 · DOI 10.1002/lary.26489
mTOR co-targeting strategies for head and neck cancer therapy.
Wang Z, Valera JC, Zhao X, Chen Q, et al · · 2017 · cited 52× · PMID 28822012 · DOI 10.1007/s10555-017-9688-7

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Head and Neck Squamous Cell Cancer

Currently open trials in the same condition.

NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT06736379 — Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · Phase 1 · recruiting
NCT06545331 — Study of XB010 in Subjects With Solid Tumors · Phase 1 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University trials

Trials by the same sponsor.

NCT06974981 — Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry · recruiting
NCT03796884 — Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer · Phase 2 · active not recruiting
NCT03712904 — Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma · Phase 2 · terminated
NCT03807492 — Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR) · completed
NCT03477864 — Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progres · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02083692 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02083692.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing